Work

Idarucizumab in High-risk Thoracic Surgery.

Year: 2018

Type: article

Abstract: Direct oral anticoagulants have suggested a favorable profile compared with vitamin K antagonists. However, the lack of treatment to reverse the effect of direct oral anticoagulants has limited its use in some patients who require rapid reversal of anticoagulation, as those included in the transplant waiting list. Idarucizumab is a recently approved drug to reverse the anticoagulant effect of dabigatran. However, the clinical experience when using this drug is scarce. Herein, we present a clinical case on anticoagulation reversal with idarucizumab to perform heart and lung transplantation in a patient with Eisenmenger syndrome.

Source: Europe PMC (PubMed Central)

Authors: R López-Vilella, J Sanz-Sánchez, I Sánchez-Lázaro, E Marques-Sule, J Rueda-Soriano, L Almenar-Bonet

Institutions: Hospital Universitari i Politècnic La Fe, Universitat de València

Language: English

Topic: Atrial Fibrillation Management and Outcomes

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W2809967296

FWCI: 0.378

Cites: 13

Cited by: 3

Related to: 10